FabRx announces launch of M3DIMAKER, first pharmaceutical 3D printer for manufacturing personalised medicines

M3DIMAKER

FabRx announces launch of M3DIMAKER

FabRx Ltd., the innovative pharmaceutical biotechnology spin-out from University College London (UCL) pioneering 3D printing of pharmaceuticals, has released the first pharmaceutical 3D printer M3DIMAKER for the manufacture of personalised medicines. FabRx is thrilled to announce that their cutting edge alternating nozzle 3D printing system, which has been tested in hospitals, pharmacies and research institutes around the world, has now been launched onto the market.

Continue reading “FabRx announces launch of M3DIMAKER, first pharmaceutical 3D printer for manufacturing personalised medicines”

FabRx starts crowdfunding campaign for personalised medicine 3D Printer

FabRx

FabRx starts crowdfunding campaign for personalised medicine 3D Printer

The new printer and software produces personalised medicines adapted for individual patients’ needs

FabRx is the first pharmaceutical company to work and act on the dream of personalised medicines using 3D printing technology. FabRx, in partnership with The Magic Candy Factory are working together to adapt a confectionary 3D printer to prepare medicines that are ideal for children. FabRx announces the starting of a crowdfunding campaign to raise money and create awareness about this innovative technology on Wednesday 6th December. You can find more information about the Kickstarter campaign in the following link:

https://www.kickstarter.com/projects/1533832013/1462390728?ref=363525&token=547920b8

The new printer allows the tailored manufacturing of medicines, including:

•          precise dose medication (personalised doses)
•          the combination of more than one drug (Polypill)
•          a range of formulations (tablets, capsules, chewable formulations) and
•          preparing these medicines on-demand in hospitals or pharmacies Continue reading “FabRx starts crowdfunding campaign for personalised medicine 3D Printer”

Organovo Announces Collaboration with National Institutes of Health

Organovo announced today that they are joining together with two institutes from the National Institutes of Health (NIH) to help scientists develop more reliable tools for bringing safer, more effective treatments to patients on a faster timeline. Organovo is collaborating with the National Center for Advancing Translational Sciences (NCATS) and the National Eye Institute (NEI) to develop better and more clinically predictive tissue models using Organovo’s NovoGen MMX Bioprinter®. Organovo will collaborate with NCATS and NEI in using the NovoGen Bioprinting platform to create three-dimensional, architecturally correct, functional living tissues. Continue reading “Organovo Announces Collaboration with National Institutes of Health”